These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32466789)

  • 1. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.
    Siebel C; Würthwein G; Lanvers-Kaminsky C; André N; Berthold F; Castelli I; Chastagner P; Doz F; English M; Escherich G; Frühwald MC; Graf N; Groll AH; Ruggiero A; Hempel G; Boos J
    BMC Pharmacol Toxicol; 2020 May; 21(1):37. PubMed ID: 32466789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.
    Völler S; Boos J; Krischke M; Würthwein G; Kontny NE; Boddy AV; Hempel G
    Clin Pharmacokinet; 2015 Nov; 54(11):1139-49. PubMed ID: 25925711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.
    Krischke M; Hempel G; Völler S; André N; D'Incalci M; Bisogno G; Köpcke W; Borowski M; Herold R; Boddy AV; Boos J
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1175-1184. PubMed ID: 27770238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
    Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
    Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
    AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
    Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a Model-Based Dose Recommendation for Doxorubicin in Children.
    Völler S; Hempel G; Würthwein G; Boddy AV; Krischke M; André N; D'Incalci M; Bisogno G; Boos J
    Clin Pharmacokinet; 2017 Mar; 56(3):215-223. PubMed ID: 27641152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
    Barpe DR; Rosa DD; Froehlich PE
    Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.
    Hill CR; Cole M; Errington J; Malik G; Boddy AV; Veal GJ
    Clin Pharmacokinet; 2014 Aug; 53(8):741-51. PubMed ID: 24968986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
    Albers S; Meibohm B; Mir TS; Läer S
    Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
    Vogt W
    Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.
    Walsh C; Bonner JJ; Johnson TN; Neuhoff S; Ghazaly EA; Gribben JG; Boddy AV; Veal GJ
    Br J Clin Pharmacol; 2016 May; 81(5):989-98. PubMed ID: 26727248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer.
    van den Anker JN
    Clin Pharmacokinet; 2015 Nov; 54(11):1091-3. PubMed ID: 26123706
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration.
    Sturgill MG; Brenner DE; August DA
    Cancer Chemother Pharmacol; 1998; 41(3):193-200. PubMed ID: 9443635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
    Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
    Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
    Rudek MA; Sparreboom A; Garrett-Mayer ES; Armstrong DK; Wolff AC; Verweij J; Baker SD
    Eur J Cancer; 2004 May; 40(8):1170-8. PubMed ID: 15110880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.